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ABSTRACT
Human T-cell leukemia virus type 1 (HTLV-1) infection is endemic in Japan and several countries in 
South America, Caribbean and Africa. Endocrine and metabolic disorders have been variably reported 
to be associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Therefore, the aim of this 
article was to critically evaluate the current knowledge of the endocrine and metabolic disorders associ-
ated with HTLV-1 infection. The literature search used PubMed, Web of Science, and LILACS databases 
in the past 10 years, utilizing, in various combinations, the following keywords: HTLV-1, adult T-cell 
leukemia, diabetes mellitus, GLUT-1, osteoporosis, hypercalcemia, autoimmune thyroid disorders, dia-
betes insipidus, inappropriate antidiuretic hormone secretion; pseudohypoparathyroidism; pseudop-
seudohypoparathyroidism. The proven endocrine manifestations of the HTLV-1 infection are calcium 
disorders which occur in some patients with acute HTLV-1/Adult T-cell leukemia/lymphoma. The 
few reports about thyroid, parathyroid, antidiuretic hormone and diabetes mellitus are insuffi cient to 
prove a causal association with HTLV-1 infection. The evidence for an association between endocrine 
disorders and HTLV-1 infection in general, and in asymptomatic patients is lacking. Given all these 
uncertainties, the endocrine expression of the HTLV-1 infection composes a promising research line 
for understanding the pathophysiology of this infection.
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INTRODUCTION
The human T-cell lymphotropic virus (HTLV) 
is a retrovirus classifi ed into four types: HT-
LV-1, 2, 3 and 4.1,2 Despite that 95% of the 
HTLV-1 infected individuals remain asympto-
matic, this infection can cause syndromes such 
as adult T-cell leukemia/lymphoma (ATLL), 
HTLV-1-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP), polymyositis, ar-
thritis and infective dermatitis.1-3
The HTLV-1 infection is endemic in Ja-
pan and several countries in South America, 
Caribbean and Africa.2,4-7 The transmission 
pathways of HTLV-1 infection include verti-
cal, parenteral and sexual transmission.2,7 Risk 
factors associated with HTLV-1 infection in-
clude: hemotransfusion, low socioeconomic 
status, low education level, high-risk sexual 
behavior, anal sex, fi rst sexual relationship 
before 18 year-old and having more than 
3 sexual partners in life.7,8
Several studies have been evidencing as-
sociation between HTLV-1 infection and 
endocrinopathies and other metabolic dis-
orders such as autoimmune thyroid diseases, 
hypercalcemia, type 1 diabetes mellitus and 
pseudohypoparathyroidism.1,9-12 Due to the 
importance of these disturbances in the clini-
cal spectrum of the HTLV-1 infection, this 
study aims to review the current knowledge 
about the endocrine diseases related to the 
HTLV-1 infection.
ENDOCRINE-METABOLIC 
DISORDERS ASSOCIATED WITH 
HTLV-1 INFECTION
CALCIUM DISORDERS
Hypercalcemia and osteoporosis
Adult T-cell leukemia/lymphoma (ATLL) asso-
ciated with the HTLV-1 infection is a neoplasia 
with an average survival of six months in the 
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acute form.13-15 It affects 5% of the patients, starting in the av-
erage age of 58 years-old.16-17 In 70%-80% of the acute ATLL 
form, the patients develop the humoral hypercalcemia of ma-
lignancy (HHM), a paraneoplastic syndrome characterized by 
hypercalcemia, osteoporosis and osteolytic lesions.13-15,18,19 This 
suggests that there should be released or expressed molecules in 
ATLL cells performing a crucial role in HHM etiology.20 
The HHM of patients with acute ATLL is caused by 
mechanisms that act synergistically, affecting directly or 
indirectly the osteoclastic differentiation. The most stud-
ied mechanisms are: (I) receptor activator of the nuclear 
factor-kB ligand (RANKL); (II) osteoprotegerin (OPG); 
(III) parathyroid hormone-related protein (PTHrP); (IV) 
pro-inﬂ ammatory cytokines; (V) macrophage inﬂ amma-
tory protein-1 alpha (MIP-1 alpha); (VI) nonstructural viral 
protein Tax; (VII) viral envelope protein, Gp-4; and (VIII) 
metalloproteinases. 
RANKL
RANKL (receptor activator of the nuclear factor-kB ligand) 
is a surface protein, part of the superfamily of TNF (tumor-
al necrosis factor), which when bound to their receptors 
(RANK) expressed in the osteoclastic precursors stimulates 
its differentiation in mature osteoclast, increasing its bone 
resorption and causing hypercalcemia and osteoporosis.21 
Patients with ATLL and hypercalcemia present increase of 
the expression of RANK.14,18 Thus, the invasion of the bone 
marrow by ATLL cells expressing RANKL in its surface in-
duces osteoclastic differentiation causing hypercalcemia.
Osteoprotegerin
Osteoprotegerin (OPG) is a soluble receptor from the fam-
ily of the tumoral necrosis factor (TNF) produced by sev-
eral types of cells, including osteoblasts. It acts as a decoy 
receptor by binding and neutralizing RANK and its effect 
in the differentiation and proliferation of the osteoclasts.22 
Studies in vitro have shown that OPG inhibits the osteo-
clastogenesis, blocking the bone resorption by mature os-
teoclast and promoting osteoclastic apoptosis.14 Mice with 
increased expression of OPG are osteopetrotic23 while 
animals with defi ciency of OPG present osteoporosis.24 
Nosaka et al. suggest that the decrease in the production of 
OPG in patients with ATTL can be one of the pathogenic 
mechanisms of the hypercalcemia.18
PTHrp
The PTHrP (parathyroid hormone-related protein) is a 
peptide that binds to PTH1R (parathyroid hormone-1 
receptors) promoting osteoclastic resorption, suppres-
sion of the osteoclastic activity and increase in the cal-
cium urinary resorption. Patients infected by HTLV-1 
present elevation of the PTHrP levels, mainly those with 
ATLL and HAM-TSP.1 Fukumoto et al. evidenced hy-
percalciuria and increase of urinary excretion of cyclic 
AMP in 10 patients with ATLL, suggesting that the hy-
percalcemia was caused by the chronic increased mobi-
lization of calcium.25 Studies of cellular lineages infected 
by HTLV-1 have disclosed the production of a factor that 
stimulated the activity of the adenylyl cyclase in osteob-
lastic membranes, being the mRNA (messenger RNA) 
from these cells homologous to the mRNA of the PTHrP 
gene.26,27 A study with ATLL patients, normo or hyper-
calcemic, has revealed that a rise in the expression of the 
PTHrP gene is directly proportional to the population of 
leukemic cells.28 The trans-activation of the promoter 
of PTHrP by the protein Tax from HTLV-1 virus seems to 
be one of the mechanisms of expression of the PTHrP 
gene in the infected cells.28 The PTHrP also boost the 
production of pro-inflammatory cytokines, stimulating 
the synthesis of interleukin 6 (IL-6) by osteoblasts and 
IL-8 and TNF-alpha by non-osseous tissues, for example 
the immune system.20 Although the PTHrP and its recep-
tors are upregulated in the ATLL, HAM/TSP and asymp-
tomatic carriers of HTLV-1, other host factors are neces-
sary for an accentuated expression of this peptide.17 As 
the PTHrP is not able to induce the differentiation of the 
precursor hematopoietic cells into osteoclasts and an as-
sociation between their elevated serum levels and HHM 
is not always observed, this indicates that other mecha-
nisms contribute to this process.18
Pro-infl ammatory cytokines
The interleukin 2 (IL-2) stimulates the production and 
secretion of PTHrP and the IL-5 acts synergistically with 
PTHrP in the development of hypercalcemia.29 Other cy-
tokines as TGF-beta (transforming growth factor-beta), 
TNF-alpha and IL-1 also increment the expression of 
PTHrP in a variety of tissues.29 As some patients present 
hypercalcemia without cytokine elevation, it is implicit the 
participation of other mechanisms.30
MIP-1alpha
The MIP-1alpha (macrophage inﬂ ammatory protein-1-
alpha) is a chemokine that acts as a stimulating factor 
for osteoclasts and monocyte migration (precursors of 
osteoclasts), besides inducing the expression of RANKL 
in ATLL. Okada et al., studying 24 patients with ATLL and 
hypercalcemia, found high levels of MIP-1alpha in all pa-
tients, comparing to the positive finding in only 3/37 
patients with ATLL without hypercalcemia.30 After chem-
otherapy, the decrease in the serum levels of calcium had 
a concomitant decrease in MIP-1alpha levels, supporting 
the role of this protein in the pathogenesis of hypercal-
cemia. Besides, osteoprotegerin and anti-MIP-1alpha 
antibodies inhibited the transformation of peripheral 
mononuclear cells into osteoclasts.30
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Viral tax protein
The nonstructural viral protein tax is able to activate CREB 
(cellular transcription factor CRE-binding protein), which 
renders activation of RANKL by PTHrP, resulting in hyper-
calcemia.31 The role of Tax in the pathogenesis of hyper-
calcemia in the ATLL is controversial. Studies in vivo with 
mice have not exposed accretion in the expression of Tax 
in these animals, suggesting that other factors inﬂ uence the 
regulation of PTHrP.29 On the other hand, Gao et al. have 
shown that Tax transgenic (Tax+) mice develop hypercal-
cemia, osteolytic lesions and increased osteolytic activity 
whose expression was attenuated by use of drug inhibitors 
of osteoclasts.32
Viral gp46-197 protein
Sagara et al. depicted that rabbits immunized with a HTLV-1 
structural protein (gp46-197) died due to hypercalcemia 
after receiving a boost of this peptide.14 They suggest that 
gp46-197 would be an antigen mimicry of the osteopro-
tegerin, blocking its action by sharing the same antigenic 
sites.14 The infusion of gp46-197 in mice resulted in a de-
crease in bone growth and hypercalcemia, which was curbed 
by the concurrent use of osteoprotegerin.14
Matrix metalloproteinases
The matrix metalloproteinases (MMPs) are enzymes that 
act in the extracellular matrix contributing to the formation 
and remodeling of bones and cartilages.1,33 Mice defi cient 
in a type of MMPs (MT1-MMP) present severe defects in 
the development of the axial and appendicular skeleton and 
craniofacial alterations as a consequence of the decrease of 
the proliferation of chondrocytes in the growth plate.33 Sch-
achter et al. proposed that an infection by the HTLV-1 could 
deregulate extracellular matrix proteins and its tissue inhibi-
tors leading to the development of osteoporosis in patients 
with HAM/TSP.1
PSEUDOHYPOPARATHYROIDISM AND 
PSEUDOPSEUDOHYPOPARATHYROIDISM
Pseudohypoparathyroidism (PHP) is a term used to defi ne 
a group of disorders characterized by resistance to the pe-
ripheral action of the parathyroid hormone (PTH). PHP 
is classifi ed into IA (classical presentation), IB, IC, II and 
pseudopseudohypoparathyroidism.34 Only three papers, 
indexed in MEDLINE, reporting the association between 
HTLV-1 and PHP, were published. The fi rst depicted three 
cases of PHP in patients with juvenile onset of HAM/TSP.35 
Although all presented hypocalcemia, none of them had 
hyperphosphatemia. PTH was elevated in only one patient; 
none of them demonstrated increase of the phosphorus 
urinary concentration or cyclic AMP in response to the ex-
ogenous administration of PTH. In the second article, an 
additional 11 patients were depicted.12 In this study, only 
half of the patients had hypocalcemia, one had hyperphos-
phatemia and another, elevated PTH. The serum levels of 
1,25(OH)2 vitamin D were tested in three of seven patients. 
There was no report informing if those who had normal 
levels of vitamin D have been subject to reposition of this 
vitamin. The third article portrayed a patient with HAM/
TSP and PPHP, without elevation of PTH.36 What the pa-
tients in these articles had in common was a decline in the 
activity of Gsα in the membrane of erythrocytes and renal 
resistance to PTH, which is not enough to establish a diag-
nosis of PHP or PPH.37
The authors of these articles postulate that a possible 
mechanism for juvenile onset HAM/TSP is a state of immu-
nodefi ciency caused by defi ciency of 1,25(OH)2 vitamin D 
as a result of PHP.35 Besides, they report that the HTLV-1 
infection is not an inductor factor for PHP, but that PHP is 
a risk factor for a precocious onset of HAM/TSP in patients 
infected through blood transfusion, explaining this way the 
more precocious onset of HAM/TSP in these patients.12,36
THYROID DISORDERS
Autoimmune thyroid diseases
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are dis-
eases characterized by humoral and cellular autoimmunity.38,39 
The retrovirus, being able to integrate in the cellular genome, 
can participate in the development of autoimmune disease, 
either through the expression of foreign antigens through al-
teration of expression of autoantigen or through the unbal-
ance of subpopulations of serum lymphocytes.40-42 Some evi-
dences relate HTLV-1 infection as a possible pathogenic factor 
in the autoimmune thyroid diseases.
Higher prevalence of seropositivity for HTLV-1 in 
patients with HT
Kawai et al., studying 144 patients with HT, found a higher fre-
quency of seropositivity for HTLV-1.43 In the same study, 33.3% 
of the HAM/TSP patients had evidence of HT, comparing with 
a 1.7% prevalence in the same region. Mizokami et al. found 
a higher HTLV-1 seropositive prevalence in individuals with 
HT and positive antithyroid antibodies.44 Mine et al., study-
ing 1,019 blood donors found a stronger association between 
HTLV-I seropositivity and the presence of antithyroid antibod-
ies, when compared with seronegative controls.45 Akamine et 
al. demonstrated a high prevalence of antithyroid antibodies in 
carriers of the virus and ATLL patients.10 Lagaye et al., studying 
patients with polyendocrinopathies, did not detect HTLV-1 an-
tibodies through ELISA and Western Blot; but when Southern 
Blot and PCR methods were used, the viral DNA was detected 
in 35% of the patients.42 Concerning to GD, Smikle et al. found 
a 6% HTLV-1 positivity for GD patients, comparing to a 4% 
seropositivity in healthy controls, which does not favor the as-
sociation between HTLV-1 infection and GD.11
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Detection of viral products in the follicular cells of 
patients with autoimmune thyroidopathy 
Kawai et al. found HTLV-1 viral proteins in thyroid tissue in 
HTLV-1 and TH patients46 and, in another study, they de-
tected the HTLV-1 viral protein gp46 in thyroid follicular 
cells indicating previous thyroid tissue viral infection and 
probable association between these two diseases.47 Filho 
et al., studying thyroid tissue from cadavers with GD and 
HT and normal controls, found 83% and 85% positivity 
for p19(gag) and gp21(env) HTLV-1 proteins, respectively, 
without any clinical evidence of HTLV-1 infection.48 These 
fi ndings did not confi rm the role of HTLV-1 in the patho-
genesis of thyroid autoimmunity, but suggest that they can 
be the result of cross reaction, molecular mimicry or endog-
enous retrovirosis.
Detection of a higher viral load of HTLV-1 in 
patients with autoimmune thyroid diseases 
Matsuda et al. found a higher HTLV-1 proviral load in the 
peripheral blood of patients with HT and GD comparing to 
asymptomatic carriers of the virus.49 In this study there was 
no association between the proviral load and the titles of an-
tithyroid antibodies. As the proviral load is a determinant fac-
tor for the development of the virus clinical manifestations 
it is possible that it takes part in the pathogenesis of autoim-
mune thyroid disease in HTLV-1 infected patients. 
Association between HTLV-1 infection and CTLA-4 
polymorphisms
The CTLA-4 (cytotoxic T-lymphocyte antigen-4) is a mol-
ecule that decreases the immune response of T-cells, being 
implicated in the pathogenesis of autoimmune thyroid dis-
eases.50 Thus, polymorphisms of this gene could be associ-
ated with a higher positivity to thyroid diseases in HTLV-1 
infected patients. Nevertheless, Tomoyose et al. did not fi nd 
difference in the frequency of this polymorphism in patients 
with TH with or without positive HTLV-1 test, concluding 
that HTLV-1 infection is not regulated by CTLA-4.51
Reports of autoimmune systemic manifestation of 
HTLV-1 associated with autoimmune thyroidopathies
Yamaguchi et al. described a higher prevalence of DG in 
patients with uveitis associated with HTLV-1.52 Kawai et al. 
reported three patients with uveitis and arthritis related to 
HTLV-1 and Graves’ disease, suggesting that this thyroid dis-
ease was associated with the viral infection.53
HTLV-1 infection causing host immune derangement
Oh et al. reported that the HTLV-1 Tax protein downregu-
lates FOXP3, a gene which codifi es a fundamental protein 
for the development and function of the T-cells.54 Mutations 
in FOXP3 results in alterations in subpopulations of regu-
lator T lymphocytes, causing a primary immunodefi ciency 
syndrome called IPEX (immunodysregulation, polyendo-
crinopathy, enteropathy, X-linked), presenting multiple 
endocrine alterations, including thyroiditis and insulin-de-
pendent diabetes.55
CARBOHYDRATE DISORDERS
Type 1 diabetes mellitus
Type 1 diabetes mellitus (T1DM) is a metabolic disorder 
caused by autoreactivity of T-cells resulting in destruction of 
beta cells in pancreatic islets. Viral infections are one of the 
mechanisms through which T1DM is triggered. Endogenous 
and exogenous retroviruses have been associated with the de-
velopment of autoimmune diseases for its ability to integrate 
in the cellular genome.42
Concerning endogenous retrovirus, Conrad et al. have 
shown the presence of RNA sequences in the type K human 
endogenous retrovirus (HERV-K IDDMK1,222) in patients 
with T1DM raising the hypothesis that this virus would ex-
press a super-antigen able to trigger an immune T1DM.56 
However, Badenhoop et al.,57 Jaeckel et al.58 and Muir et al.59 
did not demonstrate differences between patients with T1DM 
and healthy controls concerning the expression of this retro-
virus. More recently, a study has shown that the HERV-K18 
retrovirus, through its CD48 region, participates in the patho-
genesis of T1DM.60
As for exogenous retrovirus, Lagaye et al. detected the pres-
ence of sequences of the region gag of the HTLV-1 in patients 
with polyendocrinopathies.12 Nevertheless, the search for anti-
bodies to HTLV-1 was negative in all patients. These fi ndings 
lead the authors to speculate if the tested gag region would be-
long to only HTLV-1 or it would be a common site to other 
retrovirus, since other HTLV-1 genomic sites (pol e pX) were 
negative, not allowing to deduce a causal relationship between 
HTLV-1 infection and T1DM.
The only study about HTLV-1 and T1DM association was 
performed in Jamaica, describing a 17% seroprevalence of HT-
LV-1 comparing to a 4% seroprevalence in the control group.11 
The authors speculated if T1DM could be triggered by HTLV-1 
infection. However, the small sample size and the fact that the 
control subjects were blood donors precluded data generaliza-
tion. Other authors did not confi rm these fi ndings.
GLUT-1 polymorphism
The transportation of glucose between the several compart-
ments of the organism is mediated through the glucose trans-
porters (GLUT).61 Recently, it was shown that HTLV-1 use 
GLUT1 to infect T-CD4 (+) lymphocytes and polymorphisms 
in its gene could predispose some individuals to HAM/TSP, 
favoring the entrance of the virus into the cells, increasing its 
viral load and then its complications.62,63 However, a recent 
study was not able to fi nd association between genetic sus-
ceptibility to HAM/TSP and g.22999g > T, g.15339T > C and 
c.-2841A > T polymorphisms of GLUT1.64
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ANTIDIURETIC HORMONE DISORDERS
Diabetes insipidus and inappropriate antidiuretic 
hormone secretion
Only four articles, published in Japanese and cited by Adachi 
et al.,9 reported ADH disorders in HTLV-1 infected patients.65-68 
Two of these articles reported fi ve HTLV-1 infected patients with 
central diabetes insipidus65,66 probably by leukemic infi ltration in 
the hypothalamus, thrombosis or infection in the central nervous 
system.9 As hypercalcemia can be expressed through nephrogenic 
diabetes insipidus, it is important to rule out this possibility when 
investigating diabetes insipidus in patients with ATLL. Other 
RANKL, Receptor activator for nuclear factor- κ B Ligand; ATLL, adult T-cell leukemia lymphoma; PTHrP, parathyroid hormone related protein; 
OPG, osteoprotegerin; MIP-1alpha, macrophage inflammatory protein-alpha; IL, interleukin; TNF, tumor necrosis factor.
articles described two patients with the syndrome of inappropri-
ate antidiuretic hormone secretion (SIADH).67,68
RESEARCH PERSPECTIVES
Figures 1 and 2 summarize the possible physiopatho-
logic mechanisms of the HLV-1 associated endocrine 
disorders. Given the uncertainties of these associations, 
a theoretical discussion of research perspectives for the 
HTLV-1 and endocrine disorder associations is present-
ed in order to stimulate works to fill the gaps of the cur-
rent knowledge.
Hypercalcemia 
Tax protein upregulates 
PTHrP expression in ATLL 
cells and stimulates RANKL 
production.
Protein Gp46 inhibits the 
OPG (decoy receptor for 
RANKL), increasing bone 
reabsortion.
Pro-inflammatory cytokines 
(IL-I, IL-6, TNF-alpha) 
simulates the production 
of PTHrP, potentiating it’s 
bone reabsortion effects.
ATLL cells produces 
MIP-1alpha (chemokine 
that acts as an 
osteoclastic simulatory 
factor), increasing gone 
reabsortion.
ATLL cells produces 
PTHrP that blinds to PTH 
receptors, simulating bone 
reabsortion.
ATLL cells express 
RANKL that simulates 
hematopoietic precursor 
into osteoclasts increasing 
bone reabsortion.
Diabetes Insipidus or SIADH
Infiltration of leukemia ATLL cells 
into hypothalamus may be the cause 
of central DI and SIADH described in 
few records.
Pseudohypoparathyroidism
Some patients with PHP may develop 
an early form of HAM/TSP due 
immunodeficiency caused by decresed 
1,25(OH)2D3 and PTH receptor 
abnormality. PHP could be a risk factor 
for HAM/TSP.
Type 1 Diabetes Mellitus
One study demonstrated a higher 
seroprevalence of HTLV-1 in patients 
with type 1 diabetes.
Autoimmune thyroid diseases
An elevated prevalence of antithyroid 
antibodies and autoimmune thyroid 
disease, especially Hashimoto’s 
thyroiditis, has been demonstrated in 
ATLL patients and HTLV-1 carriers.
HTLV-1
Infection
Figure 1: Mechanisms of hypercalcemia in HTLV-1 infection.
Figure 2: Endocrine disorders possibly associated with HTLV-1 infection.
Alves, Dourado
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CALCIUM DISORDERS
Hypercalcemia and osteoporosis
The identification of several mechanisms that lead to 
hypercalcemia in ATLL contributes to a better under-
standing of the metabolism of calcium and to studies 
aiming the application of new therapeutic agents to 
decrease the osteoclastic activity. For example, (I) os-
teoprotegerin (OPG): studies in mice with tumoral 
hypercalcemia showing a higher decrease in the serum 
calcium levels and an increase in the bone mass when 
these animals were treated with OPG when compared 
with the use of biphosphonates;69 (II) estrogens: since 
estrogen levels decreases with aging; and as the estra-
diol raise the expression of OPG, maybe its reposition 
could be one of the therapeutic alternatives in indi-
viduals with ATLL and hypercalcemia;70-72 (III) mono-
clonal antibody (denosumab) against RANKL: could 
block the osteoclastogenic actions mimicking the ac-
tion of osteoprotegerin;73 (IV) monoclonal antibody 
against PTHrP: a study showed that this therapy is able 
to block the function of PTHrP and reduce the cal-
cemia in mice;74 (V) MIP-1alpha: the therapy with MIP-
1alpha can be other potential target to the treatment of 
hypercalcemia in the ATLL;30 and (VI) biphosphonates: 
besides its antirebsorptive effect, this class of drugs has 
been shown exert antitumoral properties, limiting the 
growth of ATLL cells.75
PSEUDOHYPOPARATHYROIDISM AND 
PSEUDOPSEUDOHYPOPARATHYROIDISM
The association between PHP and HTLV-1 is contro-
versial and not proven. Thus more studies using more 
strict PHPIA and PPHP diagnostic criteria are nec-
essary in order to: (I) study the activity of the Gsα 
in patients with small stature without HAM/TSP and in 
patients with normal stature and HAM/TSP; (II) study 
other endocrine manifestations associated with Gsα dis-
orders; (III) verify the presence of hypovitaminosis D 
and its immunological collateral trigger of HAM/TSP; and 
(IV) evaluate the association between the precocious 
beginning of HAM/TSP in patients with PHP or PPHP 
who acquire HTLV-1 through blood transfusion.
THYROID DISORDERS
Autoimmune thyroid diseases
Although there is no study showing unequivocally a 
causal relationship between HTLV-1 infection and thy-
roid disorders, most of the studies support an associa-
tion between them.41 It is possible that individuals with 
a determined genetic predisposition to thyroid diseases 
have a higher probability to develop them when infected 
by HTLV-1, as the viral infection by itself is not able to 
cause it.10 Similarities between the viral and host protein 
sequence can induce a cross reaction and an immune re-
sponse against thyroid tissues or a viral infection can ac-
tivate a clone of autoreactive T-cells that would induce 
a thyroid inflammation. It is still necessary more studies 
to understand the role of HTLV-1 in the development of 
autoimmune thyroid diseases.
CARBOHYDRATE DISORDERS
Type 1 diabetes mellitus
Only one article was found in the medical literature 
reporting a higher HTLV-1 seroprevalence in patients 
with T1DM comparing to healthy controls.11 Therefore, 
more studies are needed to confirm a possible role of the 
HTLV-1 infection as a trigger of T1DM or if the findings 
reported in a single study about the theme are attributed 
to a selection bias as the control group was assembled.
GLUT-1 polymorphism
Although Costa et al. did not demonstrate mutations 
in three polymorphisms of the GLUT1, it is not possi-
ble to rule out the possibility of other polymorphisms 
implicated in the genetic predisposition to HAM/TSP.64 
Because of this, studies evaluating a larger number of 
polymorphisms are necessary to clarify this possible as-
sociation.
ANTIDIURETIC HORMONE DISORDERS
Diabetes insipidus and inappropriate 
antidiuretic hormone secretion
Due to a small number of reports in the medical litera-
ture, more studies are necessary to prove a specific role 
of the HTLV-1 in the pathogenesis of these disorders or 
if these complications are only a result of a nervous sys-
tem neoplasia or infectious aggression (ATLL immune 
suppression).
CONCLUSIONS
This review shows that the HTLV-1 endocrine associated 
diseases are mainly calcium disorders, which occurs in a 
subgroup of patients with ATLL. Why only some of the 
patients with HTLV-1/ATLL develop hypercalcemia re-
mains unanswered. The few reports about thyroid, par-
athyroid disorder, ADH and T1DM are scanty to prove a 
causal association with HTLV-1 infection. The evidence 
for an association between endocrine disorders and HT-
LV-1 infection, in general, and in asymptomatic carriers 
is lacking. Given all the uncertainties, the endocrine ex-
pression of the HTLV-1 infection composes a promising 
research line for understanding the pathophysiology of 
this infection.
HTLV and endocrine disorders
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